In a review of the literature published in The Cochrane Library, two Israeli authors conclude that the use of topical corticosteroid nasal sprays-either alone or in combination with antibiotic therapy-shows an advantage over placebo in the treatment of the symptoms of acute rhinosinusitis. But should these results change the way otolaryngologists treat a condition that is one of the most common reasons for office visits?
Explore this issue:May 2008
The researchers, Anca Zalmanovici, MD, and John Yaphe, MD, family physicians at Rabin Medical Center in Petach Tikva, Israel, reviewed four major studies. The studies, which were double-blind and placebo-controlled, included some 2000 participants in 16 countries.
In the studies reviewed, diagnosis was determined by X-ray or nasal endoscopy, and defined as having symptom duration of less than eight weeks. The intranasal corticosteroids prescribed were fluticasone propionate (Flonase), mometasone furoate (Nasonex), and budesonide (Rhinocort).